Xin Qiu

Xin Qiu is a biostatistics professional at Johnson & Johnson/Janssen Research & Development, where he has coauthored multiple clinical trial publications on esketamine for major depressive disorder, treatment-resistant depression, and suicidal ideation. He also appears as a coauthor on a paper analyzing recreational psychedelic users’ mystical experiences and wellbeing, suggesting broader involvement in mental health and psychedelic-related research. Based on the available evidence, this appears to be a statistical or clinical research role rather than a faculty appointment.